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Abstract
Background Toll-like receptors (TLRs) play an important
role in innate immunity by sensing a variety of pathogens
and inducing acquired immunity. To test our hypothesis
that dysregulation of innate immune responses acts to trig-
ger carcinogenesis, we studied the expression of TLR2 and
4 in sporadic human colorectal cancer tissue.
Methods In specimens of cancerous and noncancerous
colorectal tissue obtained at surgery, mRNA expression
levels of TLR2 and 4 were quantiWed by TaqMan real-time
polymerase chain reaction and compared between the two
types of tissue. To conWrm TLR2 and TLR4 protein expres-
sion levels, immunohistochemical analysis was performed
using the same samples.
Results TLR2 mRNA expression was signiWcantly higher
in cancerous tissue than in noncancerous tissue, while
TLR4 mRNA expression did not diVer signiWcantly. Immu-
nohistochemical analysis revealed stronger staining for
TLR2 in cancerous mucosal epithelial cells than in noncan-
cerous tissue. Staining for TLR4 in the lamina propria of
the mucosa was equally weakly positive in noncancerous
tissue and cancerous tissue. This TLR-speciWc diVerence in
expression suggested that such expression does not only
reXect a local inXammatory response to cancer inWltration,
i.e., if this was the case, both TLR2 and 4 expression would
probably be up-regulated. Our results suggest that TLR2
expression might be involved in sporadic colorectal carci-
nogenesis, whereas TLR4 is not.
Keywords Toll-like receptors (TLRs) · Colorectal 
cancer · Real-time polymerase chain reaction 
(real-time PCR) · Innate immunity
Introduction
Chronic inXammatory conditions (e.g., persistent infec-
tions) are known to be related to carcinogenesis in some
organs [1–3]. Examples include chronic Helicobacter
pylori gastritis and gastric cancer [1, 4, 5], chronic hepatitis
or cirrhosis due to hepatitis B or C virus and hepatocellular
carcinoma [1–3], and inXammatory bowel disease (IBD)
and colorectal carcinoma [6, 7].
Ulcerative colitis and Crohn’s disease are chronic IBDs
of unknown causes. A growing body of evidence suggests
that the Toll-like receptors (TLR) TLR2 and TLR4 on
intestinal epithelium and mucosal macrophages in patients
with these diseases are up-regulated as compared with
healthy persons [8,  9]. Moreover, patients with long-
standing IBD have an increased risk of colorectal cancer
[10, 11].
As for gastric cancer, investigation of TLR expression
on tumor cells of gastric carcinoma associated with H. pylori
infection has revealed the expression of TLR4, 5, and 9
(TLR9 expression is rather weak.) [12].
TLRs are a family of receptors consisting of highly con-
served molecules that sense pathogen-associated molecular
patterns (PAMPs) and activate innate immune responses.
These receptors thus play a key role in immunosurveillance
[6, 13]. Currently, 11 members of the TLR family have
been identiWed [14, 15]. TLRs are present on a variety of cells,
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mucosal epithelium, endothelial cells, and immune cells
such as macrophages, dendritic cells, and T and B cells
[16, 17]. Triggering of TLRs, with the exception of TLR3,
induces MyD88, an adaptor protein that elicits intracellular
signal-transduction agents, activates tumor necrosis factor
receptor-associated factor 6 (TRAF6), and Wnally activates
NF-B. MyD88 is essential for the production of proin-
Xammatory cytokines [18, 19]. A distinct proWle of cyto-
kines and chemokines is modulated by TLR-mediated
inXammatory and immune responses [20].
Several studies have shown that activation of the innate
immune system by engagement of TLRs to their ligands
results in antitumor eVects [21, 22]. However, the Wndings
of some investigations do not support the antitumor eVects
of TLRs [23, 24].
We focused on inXammation-induced carcinogenesis as
represented by carcinomas arising from chronic inXammatory
disorders and hypothesized that tumorigenesis involves
abnormal responses of host-innate immune systems to
diVerent kinds of antigens. Recent studies have clariWed
that TLRs are functionally associated with tumor progres-
sion in tumor cell lines; for example, engagement of TLRs
increases tumor growth and tumor immune escape and also
induces apoptosis resistance and chemoresistance in some
tumor cells [25, 26]. To gain a better understanding of the
role of TLRs, we considered it practical to estimate the total
amounts of TLRs in tissues in vivo because we assume that
interactions among various cells are caused by intercellular
signaling triggered by changes in TLR expression in the
microenvironment of tumors, resulting in tumor progres-
sion or regulation.
Therefore, to gain insight into the roles of these rela-
tively unexplored molecules, we initially studied the
expression of TLR2 and 4 in cancerous and noncancerous
colorectal tissues in patients with sporadic colorectal can-
cer. We also immunohistochemically analyzed the expres-
sion of these receptors to determine their distributions in
each type of tissue.
Materials and methods
Human tissue samples and internal control
Surgical specimens of colorectal tissues were obtained
from 50 patients with colorectal carcinoma at Toho Univer-
sity Sakura Medical Center after their agreement. About
30 mg each of cancerous tissue (CT) and noncancerous
tissue (NCT), situated proximally to the tumor and macro-
scopically free of disease (a subsequent microscopic
analysis showed no cancer cells), was taken immediately
after surgery. TLR2 and TLR4 mRNA expression in each
tissue sample was measured by quantitative real-time PCR.
CT specimens consisted mainly of the surface layer of the
tumor, and NCT specimens consisted mainly of the surface
layer of the normal mucosal.
To select the optimal internal control, we used TaqMan®
Human Endogenous Control Plate (Applied Biosystems
Inc.), which contains TaqMan primers and probes for 11
commonly used housekeeping (HK) genes and 1 internal
positive control sequence. NCT and CT specimens obtained
from patients with colorectal cancer were used as test spec-
imens (8 samples/4 patients) to determine the most suitable
internal references. One of the NCT samples was used as a
calibrator. Following the manufacturer’s instructions, we
investigated potential controls and chose one gene, -actin
(BA) as an internal control. Relative quantiWcation was
performed using this gene. Then TLR2 and 4 expression
levels were compared between the NCT and CT specimens.
This study was approved by the Ethics Committee of
Toho University Sakura Medical Center.
Patients and subgrouping
Table 1 shows the characteristics of 50 patients whose
tumors were analyzed by real-time PCR (Table 1). The 50
patients were grouped according to the histopathological
stage (pStage) of their tumors, based on the TMN classiW-
cation of the International Union against Cancer (UICC).
TLR2 and 4 expression of NCTs and CTs was assessed
according to pStage. Tumors of pStage II A or pStage II B
were collectively grouped together as pStage II, and tumors
of pStage III A, pStage III B, and pStage III C were
grouped together as pStage III because of the small num-
bers of samples. DiVerences in TLR2 and 4 expression
among each of these pStages were analyzed for both NCTs
and CTs. We also measured TLR2 and 4 expression in
diVerent parts of the colon from which the primary carci-
noma arose and compared expression levels between the
proximal colon (ascending colon and cecum) and the distal
colon (sigmoid colon and rectum).
Real-time PCR
RNA was extracted using an RNeasy® Plus Mini kit
(QIAGEN Ltd.) according to the manufacturer’s protocol.
Total RNA concentrations were measured by the absor-
bance measurement method, and a total of 1 g RNA was
used to synthesize cDNA. The cDNA was synthesized with
an AYnity Script® QPCR cDNA synthesis kit (Stratagene
Ltd.) following the manufacturer’s protocol and was used
for quantitative real-time PCR.
Quantitative real-time PCR was performed using a
Stratagene Mx3000P® QPCR System with TaqMan® Gene
Expression Master Mix. We used TaqMan® Gene Expres-
sion Assays primers and probes (Applied Biosystems Inc.).Cancer Immunol Immunother (2012) 61:71–77 73
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The thermal proWle was precycling heat activation at 95°C
for 10 min, followed by 95°C for 15 s and 60°C for 60 s for
a total of 40 cycles. Relative quantiWcation of the total gene
products in each sample was done by Ct analysis. All
samples were run in duplicate.
The primers and probes used in this study can be found
through the Assay ID in Table 2 (available online at https://
www.products.appliedbiosystems.Com/ab/en/US/adirect/ab:
jsessionid=vLDgk3bp7kHLc1yz1nr8tVyg3WtnmlGpYLv
3LCQNBJpT26wpGpGQ!-1852324903).
Immunohistochemistry
Four-micrometer-thick sections of paraYn-embedded
human specimens of normal colon and cancer were pre-
pared from tissue obtained at colectomy. Antigen retrieval
was done using Target Retrieval Solution, pH 9.0 (DAKO,
Japan), after deparaYnization and hydration of the slides.
The slides were boiled at 95°C for 40 min and then cooled
for 20 min at room temperature. Endogenous peroxidase
activity was blocked by treatment with peroxidase-blocking
solution (REAL™, DAKO). After washing with TBS, the
slides were incubated at room temperature in a moist cham-
ber for 45 min with TLR4 antibody (1:100 dilution; TLR4
Mouse Anti-human Monoclonal [6B357.1a] Antibody-LS-
B2070-LifeSpan, Bioscience) and TLR2 antibody (1:50
dilution; monoclonal antibody, clone 1030A5. 138, Abnova
Corporation). After washing with TBS, the slides were
treated with Envision (Dako Chemo-Mate; Dako Japan
Inc., Kyoto, Japan) for 30 min, followed by color develop-
ment in 3,3 diaminobenzidine tetrahydrochloride (Dako
Japan Inc., Kyoto, Japan). Finally, the slides were lightly
counterstained with hematoxylin. Isotype control immuno-
globulin G1 (IgG1) and IgG2b antibodies (DAKO, Japan)
were used as negative controls.
The degrees of expression of TLR2 and TLR4 in the
specimens were evaluated by two experienced pathologists
in our hospital and classiWed microscopically as weak or
strong.
Statistical analysis
Data are expressed as means § SD. Mean values were
compared between groups with the use of unpaired Stu-
dent’s  t-tests with two-tailed P values by StatMate III
(ATMS Co., Ltd., Tokyo, Japan). P values of less than
0.05 were considered to indicate statistical signiWcance. We
also used Kruskal–Wallis test for interstage comparisons
(P <0 . 0 5 ) .
Table 1 Characteristics of patients
a TMN classiWcation (UICC)
Age Average, 67.8 years (ranged from 52 to 90 years)
Sex Male, 22 cases female, 28 cases
Tumor 
location
Cecum, 3 cases ascending, 2 cases transverse, 
1 case
Descending, 2 cases sigmoid, 7 cases 
rectum, 27 cases
Histological 
type
Tubular adenocarcinoma, 48 cases
(well, 12 cases well-mod., 2 cases mod., 34 cases)
Mucinous adenocarcinoma, 1 case
Signet-ring cell, 1 case
pTa pT1, 4 cases pT2, 5 cases pT3, 37 cases pT4, 4 cases
pStagea I, 7 cases II, 22 cases (IIa, 19 cases IIb, 3 cases)
III, 15 cases (IIIa, 2 cases IIIb, 10 cases IIIc, 
3 cases) IV, 6 cases
Table 2 Assay ID of the primers and probes used in this study
Product type Assay ID Gene 
symbol
Gene name
Taqman(R) Gene 
Expression Assays
Hs00610101_m1 TLR2 Toll-like 
receptor 2
Taqman(R) Gene 
Expression Assays
Hs00152939_m1 TLR4 Toll-like 
receptor 4
Taqman(R) Gene 
Expression Assays
Hs99999903_m1 ACTB Actin, beta
Table 3 TLR2 and TLR4 expression compared between groups
Data are shown as mean § SD
* P < 0.05, ** P < 0.01, *** P <0 . 0 0 1
NCT (n=) CT (n=)
a Expression of TLR2 and 4 in NCT and CT
TLR2 2.61 § 1.82 (49) 6.60 § 4.15*** (50)
TLR4 1.61 § 1.04 (50) 2.17 § 2.22 (50)
b TLR2 and 4 expression in histological stages
TLR2 (pStage I) 1.76 § 0.96 (7) 7.02 § 4.55* (7)
TLR4 (pStage I) 1.14 § 0.43 (7) 2.10 § 1.41 (7)
TLR2 (pStage II) 2.89 § 2.05 (21) 10.90 § 8.61** (22)
TLR4 (pStage II) 1.11 § 0.55 (22) 1.82 § 1.74 (22)
TLR2 (pStage III) 4.02 § 3.19 (15) 7.73 § 5.55** (15)
TLR4 (pStage III) 1.72 § 0.78 (15) 1.33 § 1.09 (15)
TLR2 (pStage IV) 1.77 § 1.06 (6) 5.59 § 1.94** (6)
TLR4 (pStage IV) 1.67 § 1.04 (6) 3.50 § 3.33 (6)
c TLR2 and 4 expression in diVerent parts of the colorectum
TLR2 (proximal colon) 3.69 § 2.05 (13) 8.83 § 5.46* (13)
TLR2 (distal colon) 2.09 § 1.20 (34) 8.41 § 7.78*** (34)
TLR4 (proximal colon) 0.88 § 0.46 (34) 1.84 § 1.07* (34)
TLR4 (distal colon) 1.75 § 1.00 (13) 1.54 § 1.21 (13)74 Cancer Immunol Immunother (2012) 61:71–77
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Results
Expression of TLR2 and 4 in NCT and CT
Expression of TLR4 in NCT and CT was conWrmed in all
50 patients by real-time PCR. There was no signiWcant
diVerence in TLR4 expression between NCT and CT
(Table 3a). TLR2 mRNA expression was also conWrmed
in all 50 CTs and 49 NCTs on real-time PCR. TLR2
expression was signiWcantly higher in CT than in NCT
(P < 0.001; Table 3a).
Analysis of TLR2 and 4 expression in histological stages
TLR2 and 4 expression was compared between NCT and
CT according to pStage. There was no other signiWcant
diVerence in TLR4 expression between NCT and CT for
any pStage (Table 3b). TLR2 expression was signiW-
cantly higher in CT than in NCT for any pStage
(Table 3b).
Interstage comparisons of TLR2 and 4 expression 
in NCTs and CTs
Interstage diVerences in TLR2 and TLR4 expression were
analyzed in NCT and CT (Table 3b). In both NCT and CT,
there was no signiWcant diVerence in TLR4 expression
between pStages.
In both NCT and CT, TLR2 expression was rather high in
pStage II and III than in other pStages. However, there was no
signiWcant diVerence in TLR2 expression between pStages.
Analysis of TLR2 and 4 expression in diVerent parts 
of the colorectum
We compared TLR2 and 4 expression between NCT and
CT in two diVerent parts of the bowel, i.e., the distal colon
(the rectum and the sigmoid colon) (n = 34) and the proxi-
mal colon (the ascending colon and the cecum) (n =1 3 ) ,
since there was no signiWcant diVerence in TLR2 and TLR4
expression between pStages. There was no signiWcant
diVerence in TLR4 expression between NCT and CT in the
distal part of the colon, but was higher in CT than in NCT
in the proximal part of the colon (P < 0.05; Table 3c).
TLR2 expression was signiWcantly higher in CT than in
NCT in both the distal and proximal colon (distal colon:
P < 0.001; proximal colon: P < 0.05, Table 3c).
Immunohistochemical analysis
Immunohistochemical analysis of TLR2 and 4 was per-
formed using the same samples of NCT and CT as real-time
Fig. 1 Immunohistochemistry of TLR4 in NCT (£10, a) (£20, b) and
CT (£10, c) (£20, d). All layers of the tissue specimens were stained,
and TLR4 was strongly detected in the proper muscular layer and the
proper mucosal layer (arrows) (a, c). TLR4 was less positively stained
in the lamina propria of the mucosa in both NCT and CT (b, d)Cancer Immunol Immunother (2012) 61:71–77 75
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PCR to determine protein expression levels. All layers of
the tissue specimens were stained, and TLR4 was strongly
detected in the proper muscular layer and the proper muco-
sal layer. TLR4 was less positively (weakly) stained in the
lamina propria of the mucosa in both NCT and CT (Fig. 1a,
b, c, d). In contrast, TLR2 expression in mucosal epithelial
cells was strongly detected in CT and weakly in NCT.
Expression of TLR2 in the lamina propria was weakly
positive in both NCT and CT (Fig. 2a, b, c, d).
Discussion
In the present study, TLR4 expression did not diVer signiW-
cantly between NCT and CT. Moreover, there was no sig-
niWcant diVerence in TLR4 expression between NCT and
CT in any each histological stage. In contrast to TLR4,
TLR2 was signiWcantly up-regulated in CT as compared
with NCT. TLR2 expression was signiWcantly higher in CT
in each pStage of cancer as well. It was thought that the
present study was not biased by pStage.
Immunohistochemical analysis showed similar weak
positive TLR4 expression in NCT and CT in the lamina
propria of the mucosa. TLR2 expression was more strongly
positive in CT than in NCT. The site of expression was
localized: TLR2 was strongly expressed in mucosal epithelial
cells and weakly expressed in mucosal inWltrating lympho-
cytes. Indeed, these results are intriguing because both
TLR4 and 2 would be expected to be up-regulated in CT as
compared with NCT if increased expression was caused
solely by inXammatory cell inWltration in response to CT.
Fukata et al. [24] have reported that TLR4 expression
might be a risk factor for tumorigenesis because TLR4 is
overexpressed in colitis-associated adenocarcinoma (CAC)
in patients with IBD. However, our Wndings do not fully
support their results. TLR4 recognizes gram-negative
bacteria by binding LPS, a membrane component of gram-
negative bacteria. TLR4 is also now known to recognize
other endogenous ligands [13, 19]. TLR2 recognizes cell
membrane components of gram-positive bacteria, peptido-
glycan, zymosan, and bacterial lipopeptides by forming
heterodimers with other TLR family members [9, 27, 28].
On the basis of these Wndings, we assumed that no dramatic
increase in TLR4 expression levels in cancerous colorectal
tissues suggests that TLR4 is minimally or rarely involved
in sporadic colorectal carcinogenesis as compared with
CAC or that TLR4 expression is regulated by some special
systems in CT. Up-regulation of TLR2 in CT implies
that TLR2 may try to potentiate compensatory immune
responses in the presence of restricted TLR4 expression in
the tumor microenvironment or that some TLR2-speciWc
ligands (e.g., gram-positive bacteria) may be responsible
Fig. 2 Immunohistochemistry of TLR2 in NCT (£10, a) (£20, b) and
CT (£10, c) (£20, d). All layers of the tissue specimens were stained,
and TLR2 expression in mucosal epithelial cells was stronger in CT
than in NCT (arrow heads). Expression of TLR2 in the lamina propria
was weakly positive in both NCT and CT (a, b, c, d)76 Cancer Immunol Immunother (2012) 61:71–77
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for carcinogenesis of the large intestine. These Wndings
may provide clues to the mechanisms of carcinogenesis in
the tissue microenvironment.
As for diVerences in expression according to the
pStage of cancer, expression pattern of TLR2 in both
NCT and CT was rather high in pStage II and III than in
other pStages, but TLR4 expression pattern was in disor-
der. Because up-regulation of TLRs is thought to have a
role in immune activity, it seems that immune response
in association with TLR2 is most strongly activated in
pStage II or III, followed by a decrease in immune activ-
ity in pStage IV. Our results may also imply a link
between the regression of TLR2 expression in pStage IV
and the mechanism of distant metastasis. However,
there was no signiWcant diVerence in TLR2 expression
between pStages. It will be required a larger number of
samples to analyze.
Ortega-Cava et al. [6] reported that TLR4 expression
was high in the distal colon of normal mice. In contrast,
TLR2 was predominantly expressed in the proximal
segment of the colon. A similar distribution of TLR expres-
sion was conWrmed in a colitic mouse model. In the present
study, TLR2 expression in NCT was signiWcantly higher in
the proximal colon than in the distal colon. TLR4 expres-
sion in NCT was signiWcantly higher in the distal colon
than in the proximal colon. These results are consistent
with the Wndings of Ortega-Cava et al. On the other hand,
there was no signiWcant diVerence in TLR2 and 4 expres-
sion between the proximal colon and the distal colon in CT.
These expression patterns diVered from those of the colitic
mouse model of Ortega-Cava et al. Since CAC arises from
IBD, the diVerence in the TLR2, 4 expression patterns
suggests that the etiology of CAC and sporadic colorectal
cancer diVer.
In conclusion, to our knowledge, this is the Wrst study
to estimate TLR2 and 4 mRNA expression in sporadic
colorectal cancer tissue obtained surgically from patients,
not cancer cell lines alone, by means of real-time PCR and
to compare such levels with those in NCT. Interestingly,
our study unexpectedly demonstrated no apparent up-regu-
lation of TLR4 in CT, in contrast to patients with CAC.
Only TLR2 expression was up-regulated in CT. Although
fully understanding the relation between innate immunity
and carcinogenesis remains, the present work may provide
new insights into the roles of TLRs in the development of
colorectal cancer.
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